Analysis of hla alleles transcriptional deregulation
OwnerClare Puttick, Charles Swanton +1inventors
InventorsClare Puttick, Charles Swanton, Nicholas McGranahan
Life of this patent
Estimating the term…
Loading patent…
OwnerClare Puttick, Charles Swanton +1inventors
InventorsClare Puttick, Charles Swanton, Nicholas McGranahan
Estimating the term…
Methods for determining whether an HLA gene has deregulated expression in a sample from a subject. The methods comprise obtaining RNA sequence data from the sample; obtaining a reference sequence that is specific to one or more HLA alleles identified to be present in the subject; and aligning the RNA sequence data from the sample to the genomic reference sequence and determining whether one or more HLA alleles in the reference sequence have deregulated expression based on one or more metrics derived from the aligned RNA sequence data at mismatch positions between homologous alleles and/or at one or more non-canonical splice junctions in the reference sequence, and one or more corresponding reference values. Methods of providing or identifying a therapy, as well as prognostic methods are also described, as well as related systems and products.
A method for determining whether an HLA gene has deregulated expression in a tumour sample from a subject, the method comprising:
The method of any preceding claim, wherein the RNA sequence data is next generation sequencing data, short reads sequence data, and/or whole transcriptome sequencing data, and/or wherein the RNA sequence data is bulk RNA sequence data or single cell RNA sequencing data.
The method of any preceding claim, wherein the reference sequence is a genomic reference sequence or a transcriptomic reference sequence, and/or wherein obtaining the reference sequence comprises combining reference sequences for a plurality of HLA allele previously identified to be present in the subject, and/or wherein obtaining the reference sequence comprises identifying one or more HLA alleles present in the subject and combining reference sequences for the one or more alleles identified to be present in the subject,
The method of any preceding claim, wherein the method further comprises obtaining one or more corresponding reference values by:
The method of any preceding claims, wherein the one or more reference values are derived from one or more normal samples, optionally wherein the one or more normal samples are matched normal samples or normal samples with the same HLA allele as the tumour sample.
The method of any preceding claim, wherein the RNA sequence data comprise RNA sequencing reads, optionally wherein the method further comprises obtaining a normalised read depth for one or more HLA alleles, wherein the normalised read depth is normalised for total coverage and/or allele length, or wherein the method further comprises calculating an adjusted read number for one or more HLA alleles, wherein the adjusted read number for an allele takes into account the number of reads that map uniquely to the allele, the number of reads that map uniquely to the homologous allele, and the number of reads that map to both the allele and the homologous allele,
The method of any preceding claim, wherein the deregulated expression is an altered level of expression of a specific HLA allele compared to a control level, and wherein the method comprises excluding any allele for which the numbers of reads that map uniquely to one of the two homologous alleles is below a predetermined threshold, optionally wherein the predetermined threshold is 30%, 40%, 50% or 60%, and/or
The method of any preceding claim, further comprising determining whether there is allelic imbalance between two homologous alleles in the sample by comparing the read depths at mismatch positions between the two alleles, optionally wherein the comparing uses a statistical test, optionally a Wilcoxon test, and/or wherein the read depths are adjusted such that each sequence read in the RNA sequence data that maps to a mismatch position is counted only once.
The method of any preceding claim, wherein the sequence data comprises sequencing reads and aligning RNA sequence data to the reference comprises selecting reads that align to a region comprising the HLA locus in a standard reference sequence and/or selecting reads that contain a sequence that matches to a sequence from a set of target reference sequences and/or selecting reads that do not align to any regions of a standard reference sequence, optionally wherein the match is an exact match, and/or wherein the set of target sequences is a set of k-mers created from the subject-specific reference sequence, and/or wherein the set of target reference sequences comprises all sequences of a predetermined length, such as e.g. 30 bases, in the reference sequences of a set of possible alleles in the subject.
The method of any preceding claim, wherein the HLA allele is a class I HLA allele, or wherein the HLA allele is a class II HLA allele.
The method of any preceding claim, wherein the method comprises excluding any HLA gene for which the numbers of reads that map to more than one HLA gene is above a predetermined threshold, optionally wherein the predetermined threshold is 5%, 10%, 15% or 20%.
The method of any preceding claim, wherein obtaining the reference sequence comprises identifying one or more non-canonical splice junctions in the reference sequence by aligning the RNA sequence data from the sample to reference sequences for one or more HLA alleles identified to be present in the subject, and/or
The method of any preceding claim, wherein a read that includes a non-canonical splice junction is a read that comprises sequence from two exons that surround a candidate exon and do not comprise sequence from the candidate exon, a read that comprises sequence from a first exon and a subsequent exon wherein the junction between the first and subsequent exon is within the sequence of the first exon, a read that comprises sequence from a first exon and a preceding exon wherein the junction between the first and preceding exon is within the sequence of the first exon, a read that comprises sequence from an exon and at least a part of the subsequent intron, or a read that comprises sequence from an exon and at least a part of the preceding intron.
The method of any preceding claim, wherein the HLA gene is a class I gene, and wherein the non-canonical splice junction involves one or more of exons 2, 3, 4, 5 and introns 2, 3, 4, 5, optionally wherein the non-canonical splice junction results in partial or complete exon skipping of exon 5, partial or complete intron retention of intron 5, partial or complete exon skipping of exons 2, 3 and/or 4, partial intron retention of introns 3 and/or 4, optionally wherein the non-canonical splice junction involves exon skipping of exon 3 and/or exon 5,intron retention of intron 5, complete exon skipping of exon 5, complete exon skipping of exon 3, partial intron retention of intron 5, partial skipping of exons 2, 3 and/or 4, and/or partial intron retention of introns 3 and/or 4.
The method of any preceding claim, wherein the reference sequence is a genomic reference sequence and wherein aligning the RNA sequence data from the sample to the genomic reference sequence comprises aligning the RNA sequence data or selected reads from the RNA sequence data to the genomic reference sequence provided as a genomic sequence and an indication of the locations of introns and exons in the genomic sequence, optionally wherein the locations of introns and exons in the genomic sequence comprises one or more known (canonical) locations of introns and exons, optionally wherein the method further comprises identifying using the aligned RNA sequence data the location of one or more candidate non-canonical splice junctions,
The method of any preceding claim, further comprising identifying one or more somatic mutations in the sequence of one or more HLA alleles present in the subject, optionally wherein identifying one or more somatic mutations in the sequence of one or more HLA alleles present in the subject comprises aligning DNA sequence from the sample to the genomic reference, and/or wherein determining whether one or more HLA alleles in the reference sequence have deregulated expression comprises determining the number of reads that comprise the one or more somatic mutations.
The method of any preceding claim, further comprising obtaining said sample from said subject, and/or obtaining RNA and/or DNA sequence data from a tumour sample, and optionally a normal sample, that has been previously obtained from the subject.
The method of any preceding claim, further comprising providing to a user, optionally through a user interface, one or more of:
A method of providing an immunotherapy for a subject, the method comprising:
Dependencies are inferred from the claim text.